Australia was one of the first countries to introduce government-funded unrestricted access to direct-acting antiviral (DAA) therapy, with 88,790 treated since March 2016. However, treatment uptake is declining which could potentially undermine Australia's progress towards the WHO HCV elimination targets. Using mathematical modelling, we updated estimates for those living with chronic HCV in Australia, new cases of decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and liver-related mortality among the HCV-cured and viraemic populations from 2015 to 2030. We considered various DAA treatment scenarios incorporating annual treatment numbers to 2020, and subsequent uptake per year of 6,790 (pessimistic), 8,100 (intermediate), and 11,310 (optimistic). We incorporated the effects of excess alcohol consumption and reduction in progression to DC and HCC among cirrhosis-cured versus viraemic individuals. At the end of 2020, we estimated 117,810 Australians were living with chronic HCV. New cases per year of DC, HCC, and liver-related mortality among the HCV viraemic population decreased rapidly from 2015 (almost eliminated by 2030). In contrast, the growing population size of those cured with advanced liver disease meant DC, HCC, and liver-related mortality declined slowly. The estimated reduction in liver-related mortality from 2015 to 2030 in the combined HCV viraemic and cured population is 25% in the intermediate scenario. With declining HCV treatment uptake and ongoing individual-level risk of advanced liver disease complications, including among cirrhosis- cured individuals, Australia is unlikely to achieve all WHO HCV elimination targets by 2030.
|Issue number||9 September|
|Publication status||Published - Sept 2021|
Bibliographical noteFunding Information:
Funding:TheKirbyInstituteisfundedbythe AustralianGovernmentDepartmentofHealthand isaffiliatedwiththeFacultyofMedicine,UNSW Sydney.Theviewsexpressedinthispublicationdo notnecessarilyrepresentthepositionofthe AustralianGovernment.GJDhasreceivedresearch grantfundingfromGilead,Merck,andAbbvie.JG hasreceivedresearchgrantfundingfrom Camurus,Cepheid,Gilead,Hologic,Indivior, Merck,andAbbvieunrelatedtothiswork.JGis supportedbyanAustralianNationalHealthand MedicalResearchCouncil(NHMRC)Investigator Grant(#1176131).Fundersdidnothaveany additionalroleinthestudydesign,datacollection, andanalysis,decisiontopublish,orpreparationof themanuscript.Thespecificrolesofeachauthor arearticulatedinthe‘authorcontributions’section.
© 2021 Kwon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.